Related Experiment Videos

New stimulation regimens with recombinant FSH (Puregon) in in-vitro fertilization

¹NV Organon, Oss, The Netherlands.

European Journal of Obstetrics, Gynecology, and Reproductive Biology

|July 31, 1999

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments.

Human reproduction (Oxford, England)·2001

A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles.

Human reproduction (Oxford, England)·2001

Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation.

Human reproduction (Oxford, England)·1999

A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation.

Human reproduction (Oxford, England)·1999

A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients.

Human reproduction (Oxford, England)·1998

Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group.

Fertility and sterility·1998

See all related articles